Fate

FATE NASDAQ
22.46
+0.32
+1.45%
盘后: 22.46 0 0.00% 17:04 07/16 EDT
开盘
22.09
昨收
22.14
最高
22.75
最低
21.83
成交量
67.02万
成交均量(3M)
79.68万
52周最高
22.75
52周最低
8.64
换手率
1.03%
市值
14.64亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Fate FATE股票价格,Fate股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
展开 >

最近浏览

名称
价格
涨跌幅